Pembrolizumab Demonstrates Improved Overall Survival as Initial Treatment of Recurrent or Metastatic HNSCC – APhA submits compounding comments to FDA. – (866) 348-2889.
Merck’s pembrolizumab (Keytruda) injection, an anti-PD-1 therapy, in combination with chemotherapy has been found to reduce the risk of death by 40% in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors expressed PD-L1 with a combined positive score equal to or less than 20. In the Phase 3 KEYNOTE-048 trial, the combination demonstrated significantly longer overall survival when compared to the regimen of cetuximab with carboplatin or cisplatin plus 5-fluorouracil (Extreme), which is the current standard of care.1
The data was announced today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.1